Skip to main content
NUTRITION 2023 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Session: Nutrients and Inflammation (Oral 10)

(OR10-05-23) Anti-inflammatory Effects of a Phenolic-Enriched Maple Syrup Extract in a Lipopolysaccharide-Induced Peritonitis Mouse Model

Sunday, July 23, 2023
2:48 PM – 3:00 PM ET
Location:  Constitution B

    Presenting Author(s)

  • TP

    Tess Puopolo

    Ph.D Candidate
    University of Rhode Island
    Kingston, Rhode Island, United States

    Disclosure(s): No relevant financial relationship(s) with ineligible companies to disclose.

    • Co-Author(s)

  • HL

    Huifang Li (she/her/hers)

    PhD candidate
    University of Rhode Island
    kingston, Rhode Island, United States

  • HM

    Hang Ma, n/a

    University of Rhode Island
    Kingston, Rhode Island, United States

  • CL

    Chang Liu

    University of Rhode Island

  • NS

    Navindra P. Seeram

    University of Rhode Island

Disclosure(s):
Tess Puopolo: No relevant financial relationship(s) with ineligible companies to disclose.
Objectives: Maple syrup is a popularly consumed plant-derived natural sweetener containing sucrose, vitamins, minerals, organic and amino acids, phytohormones, and phytochemicals (predominantly, phenolics). Our group has previously reported the phytochemical characterization and biological effects of maple syrup and a phenolic-enriched maple syrup extract (MSX). While MSX shows anti-inflammatory effects in vitro, there is limited data available on its in vivo effects at dietary relevant doses. Herein, we evaluated the anti-inflammatory effects of MSX in a lipopolysaccharide (LPS)-induced peritonitis mouse model.

Methods: MSX was orally administered to mice at 15 mg/kg (0.0125% bw), 30 mg/kg (0.025% bw), and 60 mg/kg (0.05% bw) for ten days. Then mice were challenged with LPS via intraperitoneal injection. Control and model groups were orally administered an equal volume of phosphate-buffered saline (PBS), and on day ten, the mice were exposed to PBS and LPS (1 mg/kg), respectively, via intraperitoneal injection. Peritoneal fluid, serum, and major organs were collected for the measurement of inflammatory cytokines.

Results: Simulation with LPS increased the serum TNF-ɑ, IL-6, and IL-1β expression by 84.05, 1281, 29.99 pg/mL, respectively, as compared to the control group. Further, peritoneal TNF-ɑ, IL-6, and IL-1β were also increased by 1.286, 1281, and 24.35 pg/mL, respectively, in the LPS-induced group. MSX (at 15 and 60 mg/kg) suppressed the serum TNF-ɑ by 20.92 and 59.2 pg/mL and reduced peritoneal TNF-ɑ by 1.030 pg/mL (at a 60 mg/kg dose) as compared to the model group. MSX (at 60 mg/kg) counteracted LPS-elevated serum IL-6 by 440 pg/mL and peritoneal IL-6 by 676.1 pg/mL. MSX (at 15 and 60 mg/kg) also suppressed LPS-stimulated serum IL-1β by 15.39 and 21.51 pg/mL respectively. Furthermore, MSX decreased the LPS-elevated expressions of TNF-ɑ, IL-6, and IL-1β in the major organs. MSX (at 15 mg/kg) decreased IL-6 in the lung by 259.2 pg/mL as compared to the model group. MSX (at 60 mg/kg) also reduced TNF-ɑ (in the liver by 4.91 pg/mL), IL-6 (in the heart, lung, and spleen by 440.7, 627.9, and 364.1 pg/mL, respectively), and IL-1β (in the liver by 151.8 pg/mL).

Conclusions: Overall, the in vivo anti-inflammatory effect of MSX supports its potential for nutraceutical applications.

Funding Sources: This project was supported by the Quebec Maple Syrup Producers (Quebec, Canada).